Prognostic significance of RBP2-H1 variant of JARID1B in melanoma
Autor: | Barbara W. Chwirot, Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Jumonji Domain-Containing Histone Demethylases Cancer Research Skin Neoplasms Cellular differentiation Context (language use) Kaplan-Meier Estimate Patient’s survival lcsh:RC254-282 Epigenesis Genetic Malignant transformation 03 medical and health sciences 0302 clinical medicine Biomarkers Tumor Genetics medicine Humans Protein Isoforms Epigenetics Melanoma biology Nuclear Proteins Prognosis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Immunohistochemistry Gene Expression Regulation Neoplastic Repressor Proteins Alternative Splicing JARID1B 030104 developmental biology Oncology Lymphatic Metastasis 030220 oncology & carcinogenesis Cutaneous melanoma Disease Progression Cancer research biology.protein Demethylase RBP2-H1 variant of JARID1B Research Article |
Zdroj: | BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017) BMC Cancer |
ISSN: | 1471-2407 |
DOI: | 10.1186/s12885-017-3836-x |
Popis: | Background Histone demethylase JARID1B plays several context dependent roles in epigenetic regulation of cellular differentiation in normal development and is highly expressed in multiple human cancers. The protein is a strong transcriptional repressor capable of downregulating numerous genes. There are three splicing isoforms of JARID1B, however the links between the protein structure and function are not clear. The expression pattern of JARID1B in human melanoma seems to be different from observed in other cancers. Moreover, up to now no data on the impact of JARID1B expression in cutaneous melanoma on the patients’ prognosis have been reported. Methods We investigated immunohistochemically the association of intratumoral expression of total JARID1B protein and its RBP2-H1 isoform in primary and metastatic melanomas with prognosis for the patients. Results Expression of both total JARID1B protein and its RBP2-H1 variant was found in all the melanomas investigated. Our results indicate, however, that only high (above 90% of the cells) intratumoral expression of RBP2-H1 can be considered prognostic factor associated with worse overall survival of the patients. Conclusions Such results if considered together with data demonstrating a switch to enhanced expression of RBP2-H1 at early stages of malignant transformation of melanocytes are in agreement with hypothetical crucial role of JARID1B in the course of melanoma development and progression and suggest that altered splicing of JARID1B may be important factor increasing melanoma aggressiveness. Electronic supplementary material The online version of this article (10.1186/s12885-017-3836-x) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |